Organic Nanocarriers for Bevacizumab Delivery: An Overview of Development, Characterization and Applications

Alves, Aline de Cristo Soares; Bruinsmann, Franciele Aline; Guterres, Sı́lvia Stanisçuaski; Pohlmann, Adriana Raffin

doi:10.3390/molecules26144127

Cited by 13 publications

(8 citation statements)

References 110 publications

(269 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AV-loaded PLA nanoparticles decreased survival of A549 cells and human breast cancer cells (MCF-7 and MDA-MB-231) cells (Ligiero et al, 2016). AV-loaded PLGA nanoparticles reduced more the tumor growth than the control group in a glioblastoma mice model with a decrease in the VEGF mRNA expression (Alves et al, 2021).…”

Section: Discussionmentioning

confidence: 93%

“…The development of controlled release systems for AV delivery can promote the modification of drug pharmacokinetics and, consequently, decrease the dose, toxicity, and cost due to improved efficacy (Alves et al, 2021). Therefore, nanocarrier delivery systems that can specifically deliver the drug to the cancer at high concentrations and least toxic to the normal cells have to be developed ((Abd-Rabou et al, 2016;Fekry et al, 2021).…”

Section: Research Articlementioning

confidence: 99%

See 1 more Smart Citation

Nanotherapy: New Approach for Impeding Hepatic Cancer Microenvironment via Targeting Multiple Molecular Pathways

Abdrabou

Ahmed

Mohamed³

et al. 2022

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Objective: Hepatocellular carcinoma (HCC) microenvironment has been recognized as a key contributor for cancer progression, metastasis, and drug resistance. The crosstalk between tumor cells, the vascular endothelial growth factor (VEGF), and the chemokine (C-C motif) ligand 2 (CCL2) signaling networks mediates immunoinhibitory impact and facilitates tumor angiogenesis. The current investigation aimed at exploring the potent anti-cancer activity of the newly designed nano-based anti-cancer therapy comprising anti-VEGF drug, avastin (AV), and CCR2 antagonist (CR) to counteract HCC and tracking its mode of action in vivo. Methods: The prepared AV, CR, and AVCR nanoprototypes were characterized by nanoscale characterization techniques in our previous work. Here, they are applied for unearthing their anti-cancer properties / mechanisms in hepatic cancer-induced rats via analyzing protein levels and genetic expression of the elements incorporated in the angiogenesis, apoptosis, and metastasis signalling pathways. Results: The present results revealed a significant down-regulation in the angiogenesis, survival and metastasis indices along with up-regulation in the pro-apoptotic mediators upon treatment of hepatic cancer-bearing rats with the novel synthesized nanomaterials when compared with the untreated counterparts. We showed across HCC model that anti-VEGF in combination with CCR2 antagonism therapy leads to sensitization and enhanced tumor response over anti-VEGF or CCR2 antagonism monotherapy, particularly in its nanoscale formulation. Conclusion: The present approach provides new mechanistic insights into the powerful anti-hepatic cancer advantage of the novel nanoprototypes which is correlated with modulating critical signal transduction pathways implicated in tumor microenviroment such as angiogenesis, apoptosis and metastasis. This research work presents a substantial foundation for future studies focused on prohibiting cancer progression and recovery by targeting tumor microenviroment.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Research Articlementioning

confidence: 99%

Nanotherapy: New Approach for Impeding Hepatic Cancer Microenvironment via Targeting Multiple Molecular Pathways

Abdrabou

Ahmed

Mohamed³

et al. 2022

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…Different pros and cons are reported in the literature, taking into account the polymer-based and the lipid-based systems. In detail, the former system presents higher encapsulation efficiency and a more sustained release over time in comparison to the latter ones [16].…”

Section: Introductionmentioning

confidence: 92%

Bevacizumab-Controlled Delivery from Polymeric Microparticle Systems as Interesting Tools for Pathologic Angiogenesis Diseases

et al. 2022

View full text Add to dashboard Cite

This work is a comparative study among three different biocompatible and biodegradable polymers, poly(lactic-co-glycolic acid), poly(ε-caprolactone), and poly(lactic acid), used to produce microparticles for the encapsulation of bevacizumab for drug delivery purposes. All the formulations were produced using the double emulsion water-oil-water evaporation method and characterized in terms of particle mean diameter, particle size distribution, and bevacizumab entrapment efficiency. Bevacizumab cumulative release was taken into consideration to study the dissolution kinetics from the three different polymeric delivery platforms for a period of 50 days at 37 °C in phosphate buffered saline and mathematical models of the drug release kinetic were attempted in order to describe the release phenomena from the different types of the studied microparticles. Finally, cell viability on human endothelial cell line EA.hy926 was studied to define the maximum cytocompatible concentration for each microsystem, registering the mitochondrial functionality through MTS assay.

show abstract

“…Nanocarriers can be classified as organic, inorganic, or hybrid based on the components used in their development [ 188 ].…”

Section: Novel Nanocarriers Based Treatment Approachmentioning

confidence: 99%

Adjuvant Novel Nanocarrier-Based Targeted Therapy for Lung Cancer

Sarma,

Akther,

Ahmad

et al. 2024

Molecules

View full text Add to dashboard Cite

Lung cancer has the lowest survival rate due to its late-stage diagnosis, poor prognosis, and intra-tumoral heterogeneity. These factors decrease the effectiveness of treatment. They release chemokines and cytokines from the tumor microenvironment (TME). To improve the effectiveness of treatment, researchers emphasize personalized adjuvant therapies along with conventional ones. Targeted chemotherapeutic drug delivery systems and specific pathway-blocking agents using nanocarriers are a few of them. This study explored the nanocarrier roles and strategies to improve the treatment profile’s effectiveness by striving for TME. A biofunctionalized nanocarrier stimulates biosystem interaction, cellular uptake, immune system escape, and vascular changes for penetration into the TME. Inorganic metal compounds scavenge reactive oxygen species (ROS) through their photothermal effect. Stroma, hypoxia, pH, and immunity-modulating agents conjugated or modified nanocarriers co-administered with pathway-blocking or condition-modulating agents can regulate extracellular matrix (ECM), Cancer-associated fibroblasts (CAF),Tyro3, Axl, and Mertk receptors (TAM) regulation, regulatory T-cell (Treg) inhibition, and myeloid-derived suppressor cells (MDSC) inhibition. Again, biomimetic conjugation or the surface modification of nanocarriers using ligands can enhance active targeting efficacy by bypassing the TME. A carrier system with biofunctionalized inorganic metal compounds and organic compound complex-loaded drugs is convenient for NSCLC-targeted therapy.

show abstract

Organic Nanocarriers for Bevacizumab Delivery: An Overview of Development, Characterization and Applications

Cited by 13 publications

References 110 publications

Nanotherapy: New Approach for Impeding Hepatic Cancer Microenvironment via Targeting Multiple Molecular Pathways

Nanotherapy: New Approach for Impeding Hepatic Cancer Microenvironment via Targeting Multiple Molecular Pathways

Bevacizumab-Controlled Delivery from Polymeric Microparticle Systems as Interesting Tools for Pathologic Angiogenesis Diseases

Adjuvant Novel Nanocarrier-Based Targeted Therapy for Lung Cancer

Contact Info

Product

Resources

About